| |
| Magyar Radiológusok Társasága |
|
| Kötelező, szintentartó tanfolyam |
 Rendezvény kezdete: 2008.11.06. | Rendezvény vége: 2008.11.06. |
| Tudományos információ: Prof. dr. Palkó András |
| Szervező: Cserháti Klára |
| Tel: 62/545-741, 30/907-1980 |
| Fax: 62/545-742 |
| E-mail: aklara@radio.szote.u-szeged.hu |
| Helyszín: Szeged, SZTE ÁOK Radiológiai Klinika |
Radiológus szakorvosok, szakorvosjelöltek részére- vizsgaköteles.
- időpontja: 2009. október 26-30. (össz.: 30 óra)
- helye: SZTE ÁOK Radiológiai Klinika
- jelentkezési határidő: 2009. szeptember 30.
- részvételi díj: 10.000 Ft/fő |
|
|
 |
| |
| Magyar Nephrologiai Társaság |
|
| New Era of Drug Discovery and Clinical Trials in Kidney Disease |
| Rendezvény kezdete: 2014.04.03. | Rendezvény vége: 2014.04.06. |
| Szakterület(ek): Nephrologia |
| Helyszín: Olaszország, Bergamo, |
| A rendezvény Web oldala: http://www.isnnexus.org/bergamo |
ISN Nexus Symposium on the New Era of Drug Discovery and Clinical Trials in Kidney Disease, to be held in Bergamo, Italy on April 3-6, 2014.
Abstract Submissions Deadline: January 6, 2014
Early Registration Deadline: January 27, 2014
We are very excited about this program, which will bring together scientists in academia and the pharmaceutical sector, clinicians and regulators, to define new frameworks towards efficient drug discovery and clinical trials in kidney disease.
We are especially pleased to announce that three major regulatory agencies – the FDA, the EMA and the PDMA – will be represented at the symposium, with speakers from all three giving what promises to be fascinating talks.
The Program pillars for his symposium are:
Target validation and rationale behind drug discovery
Efficient, exploratory first-in-human clinical trials for renal drugs
Global networking of clinical trials
New framework of collaboration between academia, pharma and government/regulatory authorities
Topical highlights will include:
New targets relevant to kidney disease
Unmet medical needs
Target validation
Advancement of drug discovery technologies
Exploratory clinical trials
Surrogate biomarkers
Molecular imaging
Monitoring of renal toxicity
Clinical sessions
Clinical end-points
Protocols of clinical trials
The number of newly approved drugs continue to decrease despite a growing number of kidney patients. This Nexus symposium will provide cutting-edge lectures on recent advances in drug discovery and clinical trials kidney disease.
For the most up-to-date information on this Nexus Symposium we encourage you to visit http://www.isnnexus.org/bergamo on a regular basis
We hope to see you in Bergamo, to make this symposium a success, and to help us advance kidney care around the world.
|
|
|
|
